copies/mL had their therapy for CMV retinitis discontinued. Patients had ophthalmologic examinations every 2 weeks for 3 months, monthly up to month 12, and quarterly thereafter.
Thirty-six persons met the entry criteria and discontinued their CMV prophylaxis therapy; they had a median follow-up of 90 weeks. Only one person suffered a relapse of his CMV retinitis after having a decline in his CD4+ count. Entering the study with a CD4+ count of 262 cells/µL, his count dropped to 74 cells/µL at week 40, and a bilateral relapse of CMV retinitis was noted at week 44, at which time he had a CD4+ count of 62 cells/µL. Of note, CD4+ counts for the group continued to increase over the course of the study, from a median of 287 cells/µL at baseline, to 385 cells/µL at 6 months, and to 440 cells/µL at 12 months. The percentage of persons with HIV viral loads less than 500 copies/mL remained stable.
COMMENTARY
From the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic in the early 1980s, retinitis due to CMV was one of the most feared opportunistic infections. Not only was the diagnosis of CMV retinitis a harbinger of an early death, with a median survival after diagnosis of only 6 months, but also it foretold of increasing disability through progressive visual loss. Not until 1988, with the approval of ganciclovir, could progression of the disease be effectively delayed. Still, therapy required at least daily infusions for life with therapeutic agents with significant toxicities. This study, and several others that it cites, effectively demonstrates the power of the available antiretrovirals. In addition to improvements in CD4+ cell counts in individuals receiving HAART, this study highlights the clinically significant immune recovery that can occur when HAART is effectively employed.
The issue of the quality and durability of immune recovery in persons with advanced HIV infection is a critical factor that must be balanced with the toxicities of the therapies in the determination of when to use potent antiretroviral therapy. While potent antiretroviral therapy is clearly warranted in persons with opportunistic infections associated with HIV infection, this study does not discuss the inflammatory complications associated with HAART in persons with CMV retinitis, an immune recovery uveitis that itself can lead to loss of vision. Finally, the authors note that although this and other studies have used criteria of CD4+ cell counts greater than 100 or 150 for discontinuation of anti-CMV therapy, the counts when persons actually discontinued therapy were generally much higher. The CD4+ cell count at which persons can safely discontinue therapy for CMV retinitis remains to be refined.
Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label study. Lancet. 2001; 358; 718-723 .
SUMMARY
This open study of adefovir dipivoxil included 35 adults followed at a single institution in Paris; these individuals were co-infected with human immunodeficiency virus type 1 (HIV-1) and lamivudine-resistant hepatitis B virus (HBV). Other inclusion criteria included continued therapy with lamivudine and an HIV-1 viral load less than 400 copies/mL. Persons with histories of renal or heart failure, decompensated cirrhosis, or significant hematologic problems were excluded. Adefovir 10 mg orally once daily was given for 48 weeks. Subjects were seen every 2 weeks for a month, then every 4 weeks for the next 44 weeks.
Baseline mean HBV DNA of log 8.64 copies/mL decreased by more than 4 logs, or 99.99%, at week 48. Serum alanine aminotransferase increased asymptomatically from week 8 to week 20, then declined until week 48, for a mean decline of 25 IU/L compared with baseline. No patient developed decompensated liver disease. Modest increases in serum creatinine, not attributed to adefovir, were seen in two patients. HIV-1 RNA levels and CD4+ and CD8+ cell counts did not change significantly from baseline. Two patients with persistent and low concentrations of HBV DNA seroconverted to HbeAg after 48 weeks of treatment. Adefovir, 10 mg daily, was well tolerated for 48 weeks and had activity against lamividine-resistant HBV.
COMMENTARY
In persons with access to health care, the opportunistic infections that characterized HIV infection for the first 15 years of the epidemic-Pneumocystis carinii pneumonia, toxoplasmic encephalitis, cryptococcal meningitis, disseminated Mycobacterium avium complex infection, and cytomegalovirus retinitis-have decreased dramatically due to the effective use of potent antiretroviral therapy. New cases of HIV infection are now more often transmitted heterosexually or through contaminated needles used by intravenous drug users than by sexual relations between men. Consequently, the opportunistic infections associated with these modes of transmission, hepatitis B and hepatitis C, have been associated with increasing chronicity and morbidity in HIV co-infected persons.
Approximately 10% of persons with HIV infection are co-infected with HBV. Lamivudine is effective in treating hepatitis B, but is limited by the development of resistance over time. Initial trials of adefovir dipivoxil at doses of 60 to 120 mg PO daily for the treatment of HIV infection were associated with modest antiretroviral activity and serious renal toxicity. This promising study suggests that, at the lower dose of 10 mg PO daily, adefovir may retain its activity against HBV with acceptable toxicity. A related nucleotide analogue, tenofovir, has recently been approved for the treatment of HIV infection and is also in clinical trials for the treatment of HBV.
Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA. 2001; 98:15161-15166 .
SUMMARY
In an attempt to limit the toxicity and enhance adherence to HAART for HIV infection, this study evaluated a short cycle of 7 days on, then 7 days off therapy in 10 persons chronically infected with HIV; these individuals had high CD4+ cell counts and HIV viral loads less than 50 copies/mL. At enrollment, subjects began a regimen of stavudine (30 to 40 mg bid), lamivudine (150 mg bid), indinavir (800 mg bid), and ritonavir (100 mg bid). Of eight patients who remained on the study regimen, all eight maintained viral suppression below 500 HIV RNA copies/mL (with all levels drawn at the end of off-therapy periods) for up to 68 weeks. One individual withdrew from the study at week 12, with plasma HIV RNA less than 50 copies/mL, for personal reasons. A second individual interrupted therapy for 21 days, with his plasma HIV RNA level increasing to more than 20,000 copies/mL.
No significant change in CD4+ cell counts or significant increase in HIV proviral DNA or replication-competent HIV in peripheral CD4+ cells occurred. No evidence for the development of resistance to antiretrovirals was found. After 24 weeks on intermittent therapy, there was a significant decrease in the mean serum cholesterol, mean serum low-density lipoprotein cholesterol, and mean serum triglycerides.
COMMENTARY
Interest in the intermittent treatment with HAART for HIV infection has been driven by at least four issues with therapy: the need to decrease the toxicity of HAART, the need to improve adherence to therapy, the desire to decrease the cost of therapy, and the desire to enhance HIV-specific immune responses and improve the host's ability to contain the infection. The enhancement of HIV-specific immunity via intermittent therapy has been most persuasively demonstrated in small trials of persons acutely infected with HIV. Limited data support that rationale for the use of intermittent therapy in chronically infected persons.
The needs to decrease costs and toxicities and to improve adherence to therapy provide the rationale to consider intermittent therapy for the chronically infected patient. This pilot study demonstrated that a regimen of two nucleoside analogues and two protease inhibitors could effectively limit HIV replication and decrease some toxicities of therapy when given in a cycle of 7 days on, 7 days off in eight chronically infected patients with baseline HIV viral control for between 32 and 68 weeks. Although promising, larger trials will be necessary to refine the boundaries of this therapeutic window. 
SUMMARY
Many factors influence child development. While prenatal exposures to neurotoxicants like polychlorinated biphenyls (PCBs) have been associated with development delays, it is also well known that the quality of the home environment plays a vital role. Standardized instruments are available to evaluate the level of verbal and emotional support by parents in the home, as well as mental and motor development of the child; PCBs can be measured in cord blood and maternal milk at birth and breast milk later and venous blood of the child later in life as an estimate of postnatal exposure. In this study of 171 mother-infant pairs from Germany, milk PCB level was negatively associated with mental and motor development at all ages studied (up to 42 months), while as expected, quality of home life was positively associated with development. Thus, prenatal PCB exposures at levels quite typical of current European backgrounds were detrimental to development, as was postnatal exposure through breast milk even at 42 months. Home environmental supports were positively related to mental and motor development.
COMMENTARY
The finding of effects of prenatal PCB exposure on mental and motor development corroborate findings of other studies, although the range of levels seen here are not much elevated with respect to background. The finding that PCB exposures in maternal milk even later in life (postnatally) differs from other studies, which tend to show the effect of PCBs limited to the prenatal period. Clearly, there is still much that needs to be sorted out in this complicated story. The strong effects of home environment are again evident and can balance the negative effects of PCB exposures, although another way to look at it is to say PCB exposure can cancel out the beneficial effects of a good home environment. Either way, PCBs continue to deserve their reputation as developmental toxicants that are effective even at the levels seen in the general population.
Wright R, Steinbach SF. Violence: an unrecognized environmental exposure that may contribute to greater asthma morbidity in high risk inner-city populations. Environ Health Perspect. 2001;109:1085-1089.
SUMMARY
"Grand Rounds in Environmental Medicine" is a regular feature of this journal, one of the premier environmental health sciences journals in the world. In the October 2001 issue, three cases of pediatric asthma precipitated by witnessing violent events were presented. Four cases of acute asthma exacerbation were described that occurred in immediate relation to violent events. One case involved hearing shots outside a bedroom window that were related to the fatal shooting of a peer. In another case, exacerbation of severe asthma occurred after a gang mugging; there were several recurrences when the same assailants were encountered months later. A third case involved asthma episodes in relation to assaults and threats on a school bus, while an episode in a fourth youngster was precipitated by loud violent domestic arguments between her parents.
COMMENTARY
Environmental triggers for asthma are well recognized and include cold, exercise, allergens, and emotional physical stressors. In inner-city neighborhoods especially, one emotional and physical environmental stressor that is more prevalent in the environment than in wealthier areas is violence. These cases all involve close temporal associations between violent events and the exacerbation of severe asthma episodes, some of them difficult to manage. In the catchment area of the Boston Medical Center, from which these cases were reported, 10% of the children had witnessed a knifing or shooting before they were 6 years old, almost one in five witnessed shoving, kicking, or punching, and almost one in two had heard gunshots. Even higher rates are reported in other inner-city neighborhoods. These cases and other emerging data suggest that violence in the environment may be a significant contributor to acute asthmatic incidents.
Hannerz H, Tü chsen F. Hospitalizations among female home-helpers in Denmark, 1981 -1997 . Am J Ind Med. 2002 41:1-10 .
SUMMARY
Home-care workers in Denmark are largely unskilled women who assist mentally or physically disabled people to live in their own homes. Like American home-health aides, they typically perform work in the homes of their clients; the work is often strenuous, like lifting, carrying, and washing patients; cleaning floors; and making beds. The private homes are rarely ergonomically designed, and awkward postures, long hours of standing, and other strenuous work are common. The Danish social welfare system allows calculation of Standardized (for age and sex) Hospitalizations Ratios (SHRs) to be carried out with the use of routinely collected data. Using this system, SHRs for cohorts of Danish female home helpers 20-59 years old were calculated for three time periods for a variety of diagnostic categories. Significantly high SHRs were found for musculoskeletal injuries, infectious and parasitic diseases, and diseases of the central nervous system, circulatory system, and respiratory system. Comparison of these workers to other unskilled workers found that musculoskeletal problems, varicose veins, and ischemic heart disease were significantly higher in these unskilled workers compared to others. The lung cancer rate was lower than expected. Asthma appeared to increase over the time period as well.
COMMENTARY
Home-health workers, like homemakers, have a physically demanding job with demonstrated health risks. Unlike homemakers, they have little control over their work environment, low pay, and little decision latitude, all factors that research has shown are associated with increased morbidity in the workplace. The elevated hospitalization risk associated with this work confirms this, with musculoskeletal injury, varicose veins, and heart disease significantly more common, even in comparison with other unskilled workers. Many of these workers are also exposed to passive cigarette smoking as smoking remains prevalent among the older age groups in Denmark and elsewhere, and the home-care workers have little ability to change this habit in their clients. As patterns of elder care continue to change in this country, risks to those recruited into the workforce by these changes need to be considered, especially as these individuals may not have adequate insurance. 
David Ozonoff

Health Issues in Prisons and
SUMMARY
These two studies are very similar in design and outcome. They were both undertaken to evaluate the prevalence of HIV and, in the second study, hepatitis B and C, as well as associated risk behaviors among incarcerated individuals. The studies utilized self-administered anonymous questionnaires and oral fluid specimens for antibody testing. They both had reasonable response rates (75% of 1,124 individuals and 85% of 718, respectively); they involved multiple sites, including France, Germany, Italy, the Netherlands, Scotland, and Sweden in the first paper and five of the seven Committal Prisons in the Republic of Ireland in the second. The proportion of self-reported injection drug users in each study was 27% and 29%, respectively. The overall proportion of HIV was 1% and 2%, respectively, with a higher proportion of HIV among injection drug users (4% and 6%, respectively). In the Irish study, overall 6% had hepatitis B, and 23% had hepatitis C, which again was higher in injection drug users (18% with hepatitis B, 72% with hepatitis C) but lower among firsttime entrants to the prison (HIV 0%, hepatitis B 2%, hepatitis C 3%). There were 49% in the first study and more than half in the Irish study who reported injecting drugs while incarcerated. In the latter study, nearly one fifth reported starting injecting while in prison. In the first study, 16% reported having had hepatitis B vaccine; in the Irish study, 29% of those who had been previously incarcerated had received at least one dose of hepatitis B vaccine, and of these, 82% had undergone the vaccination in prison. The authors of both studies concluded that there is a high risk of the spread of HIV in prisons and encouraged prevention strategies within prisons.
COMMENTARY
Within prisons and jails, there is a disproportionately higher frequency of blood-borne and sexually transmitted diseases, predominantly related to drug use. These two papers further corroborate this fact and raise concern about intraprison transmission of disease as a reason for higher prevalence rates. This is clearly plausible given the fact that sexual activity and drug use, particularly injection drug use, as well as other percutaneous exposures, including tattooing, occur in the incarcerated setting. There is a scarcity of sterile injection equipment (or tattooing equipment) or condoms within the setting of incarceration. Conversely, this is a high-risk population, and although high-risk activities do continue within the incarcerated setting, these high-risk activities may be at a lower frequency than they would be had the person been in the community. Many factors can affect whether transmission is greater inside the prison or outside, including the proportion of injection drug users incarcerated, which is the function of local law and drug activity in the community, the stage of the epidemics of HIV and hepatitis in the community, drug use patterns, syringe availability both outside and inside the correctional institutions, prevention programs, and the type of institution. Correctional facilities, even within one country, are extremely varied in their control of behaviors.
In Rhode Island, where routine testing of nearly all inmates occurs on entrance, nearly one third of all HIV infections are detected in the state correctional facility. An ongoing study has yet to detect a single case of intraprison HIV transmission. Whether transmission is higher within correctional facilities or outside, clearly the epidemics of HIV and other blood-borne and sexually transmitted diseases in this population need to be addressed. One example of prevention is for hepatitis B, for which we have a safe and effective vaccine. These studies highlight the need-most inmates are not yet vaccinated-and the opportunity (of those Irish prisoners who were vaccinated, most were vaccinated while incarcerated). Other preventive activities are clearly needed for this population and should be explored.
Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay area, 1998 -1999 . Am J Public Health. 2001 91(11) :1842-1846.
SUMMARY
The dramatic increase in heroin overdoses in the past decade, thought to be related to increased purity of heroin and decreased street prices, prompted this study. The authors evaluated the prevalence and risk factors for nonfatal overdose among 1,427 street-recruited heroin injectors in the San Francisco Bay area. Nonfatal overdose, considered to be a risk for fatal overdose, occurred in 48% of participants. Four variables were found to be independently associated with recent overdose: younger age, increased alcohol consumption, participation in methadone detoxification, and having been arrested three or more times in the past year. Of these four, the last had the highest odds ratio (OR; adjusted OR 2.5, 95% confidence interval [CI], 1.6, 3.9).
